Short answer
Gossamer Bio, Inc. (GOSS) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 8.01 (Other Events). First NDA submitted for seralutinib in pulmonary arterial hypertension, advancing Gossamer’s lead program toward potential commercialization.
Gossamer Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- First NDA submitted for seralutinib in pulmonary arterial hypertension, advancing Gossamer’s lead program toward potential commercialization
- Filing supported by Phase 3 PROSERA, Phase 2 TORREY, and supportive analyses
- FDA previously classified PROSERA statistical significance and treatment effect as review issues rather than filing issues
- FDA acceptance decision anticipated later in 2026; acceptance would begin substantive review, not indicate approval
- Key risks include FDA rejection, insufficient benefit-risk evidence, additional capital needs, and reliance on seralutinib’s success
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gossamer Bio, Inc. 8-K filings
Get the next GOSS 8-K as it lands
Follow GOSS for push alerts, or ask the research agent what this filing means.